Postnatal calpeptin treatment causes hippocampal neurodevelopmental defects in neonatal rats

Zhu-Jin Song1, San-Juan Yang1, Lan Han2

  • 1Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, Anhui Province, China.

Insights

Postnatal administration of calpeptin, a calpain inhibitor, impairs spatial memory and induces anxiety-like behaviors in adult rats by affecting synaptic development and inhibiting the Akt/mTOR pathway.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Pharmacology

Background:

  • Calpain inhibitors, like calpeptin, are used to reduce calpain activity.
  • Previous studies linked postnatal calpeptin to motor dysfunction, but its hippocampal effects were unknown.

Purpose of the Study:

  • To investigate the effects of postnatal calpeptin administration on hippocampus-dependent behaviors and synaptic development.
  • To elucidate the underlying molecular mechanisms in neonatal rats.

Main Methods:

  • Rats received daily intraperitoneal injections of calpeptin during early postnatal development.
  • Behavioral tests (Morris water maze, open field) assessed cognitive and anxiety-like behaviors.
  • Hippocampal synaptic morphology, dendritic spines, and protein levels (Akt, mTOR, CREB signaling pathway) were analyzed.

Main Results:

  • Calpeptin treatment impaired spatial memory and increased anxiety-like behavior in adult rats.
  • Synaptic structures, including dendritic spine number and area, were reduced, with decreased actin polymerization.
  • Neonatal calpeptin inhibited the Akt/mTOR signaling pathway, increasing SCOP and reducing phosphorylation of Akt, mTOR, and CREB.

Conclusions:

  • Postnatal calpeptin administration negatively impacts hippocampal synaptic development and function.
  • Inhibition of the Akt/mTOR pathway is a key mechanism by which calpeptin causes neurodevelopmental defects.
  • Early calpeptin exposure is a potential risk factor for neurodevelopmental disorders.

Related Concept Videos

Lumber Defects01:23

Lumber Defects

Lumber defects, which can affect both the appearance and structural integrity of wood, include a variety of growth and manufacturing flaws. Growth defects such as knots and knotholes occur where branches were once attached to the tree trunk, with knotholes forming when these knots fall out. Other natural defects include decay and insect damage, which compromise the wood's strength and durability.
Shakes are minor fractures that run along or across the wood's annual rings, while wane is...
514
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
993
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
944
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K